Deals this week: Sebacia, Roxwood Medical, Aprima Medical Software
In a Series D financing round, Sebacia, a clinical-stage private company, has raised $20m, which will be used to complete a US pivotal trial and for other commercial activities.
The round has seen the participation of existing investors Versant Ventures Management LLC, Domain Associates LLC, and Accuitive Medical Ventures and Partners Healthcare Innovation Fund. New investors such as Salem Partners as well as others have also been involved.
The company has concurrently raised $16m in debt financing from Hercules Capital.
Advanced cardiovascular speciality catheters provider Roxwood Medical has agreed to provide exclusive rights for the distribution of its medical products in the US to Abbott Vascular.
Roxwood’s anchoring catheters and microcatheters provide minimally invasive platforms for physicians to treat chronic blockages by facilitating guidewire access across the blockage.
Pursuant to the agreement, Abbott will distribute Roxwood's anchoring catheters such as CenterCross Ultra, MultiCross and microcatheters, along with its other product offerings in the US. This includes XIENCE drug eluting stent and the OPTIS integrated optical coherence tomography system.
The partnership allows Abbott to provide a comprehensive set of solutions for the most difficult cases, including chronic total occlusions, while enabling Roxwood to benefit more patients from its catheter portfolio used during complex coronary procedures.
Patient iP (Patient identification Platform), a health data solutions provider to the pharmaceutical and CRO industries, and Aprima Medical Software, an innovative electronic health records (EHR) and revenue cycle management solution for medical practices, have announced a strategic partnership to improve clinical trial recruitment efforts.
The collaboration enables the integration of Aprima’s EHR data and Patient iP's clinical trial matching solution. It also allows Aprima’s medical practice customers to access fully de-identified data processed through Patient iP's matching engine in order to find potential research participants.
The new solution enables automatic identification of patients, who meet the eligibility criteria for clinical studies, shortening the timelines and reducing the related costs.
MyndYou has announced a research partnership with the Department of Neurology and the Department of Psychiatry at Massachusetts General Hospital, US, to conduct a research trial using MyndYou’s artificial intelligence (AI) based platform.
The trial will validate the company’s AI-based technology for the remote and automated detection of subtle changes in speech patterns of Alzheimer's patients.
MyndYou’s technology is designed to detect the symptoms of Primary Progressive Aphasia (PPA), which is a neurodegenerative language disorder arising from Alzheimer's disease (AD).
OsteoRemedies, a medical device provider for complex musculoskeletal disorders, has signed an exclusive distribution agreement with Adhezion Biomedical in the US.
According to the agreement, Adhezion Biomedical has received exclusive distribution rights to OsteoRemedies’ Floraseal Microbial Sealant, which is a film-forming, cyanoacrylate-based microbial sealant used to reduce the risk of skin flora contamination throughout the surgical procedure.